

Notice of Allowability	Application No.	Applicant(s)	
	10/621,826	HUANG ET AL.	
	Examiner	Art Unit	
	Tekchand Saidha	1652	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. This communication is responsive to 1November 2005.

2. The allowed claim(s) is/are 1,2 and 6-12.

3. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a) All b) Some* c) None of the:

1. Certified copies of the priority documents have been received.

2. Certified copies of the priority documents have been received in Application No. _____.

3. Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

* Certified copies not received: _____.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.
THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.

4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.

5. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.

(a) including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached
1) hereto or 2) to Paper No./Mail Date _____.

(b) including changes required by the attached Examiner's Amendment / Comment or in the Office action of
Paper No./Mail Date _____.

Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).

6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

- 1. Notice of References Cited (PTO-892)
- 2. Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3. Information Disclosure Statements (PTO-1449 or PTO/SB/08),
Paper No./Mail Date _____
- 4. Examiner's Comment Regarding Requirement for Deposit
of Biological Material
- 5. Notice of Informal Patent Application (PTO-152)
- 6. Interview Summary (PTO-413),
Paper No./Mail Date _____.
- 7. Examiner's Amendment/Comment
- 8. Examiner's Statement of Reasons for Allowance
- 9. Other _____.

Notice of Allowability

1. Applicants' election of Group I (claims 1-2, 6-12 & 15) without traverse and amendment to claims filed on November 1, 2005 is acknowledged. Claim 15 has been cancelled by the amendment.
2. Claims 1-14 & 16-23 are pending in this application.
3. Claims **1-2 & 6-12** are allowed, subject to the following Examiner's Amendment.
4. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with S. Neil Feltham on January 3, 2006.

Cancel claims 3-5, 13-14 & 16-23.

Amend claim 4 as follows:

Claim 6, line 3, delete '90%' and replace with '95%'.

Claim 6, line 5, delete 'enzyme' and replace with 'polypeptide'.

Claim 12, line 2, after 'group consisting', insert 'of'.

Amend the Specification as follows:

Page 9, lines 23-24, delete web site "; see also www.ncbi.nlm.nih.gov/BLAST/".

Page 30, lines 2-3, delete web site "<http://www.hgsc.bcm.tmc.edu/microbial/microbialblast.cgi?organism=Rsp>" haeroides).

Page 31, lines 31-32, delete web site "<http://www.hgsc.bcm.tmc.edu/microbial/microbialblast.cgi?organism=Rsp>" haeroides).

Page 32, lines 19, delete web site "; see also www.ncbi.nlm.nih.gov/BLAST/".

5. The following is an examiner's statement of reasons for allowance:

This Application provides novel nucleic acid sequence of SEQ ID NO: 2 encoding tyrosine ammonia lyase of SEQ ID NO: 3 and a process of producing the enzyme recombinantly.

Art Unit: 1652

US20030233675-A1 (Pre-Grant Publication) discloses a DNA sequence encoding a polypeptide (accession number ADN25163), wherein the polypeptide is 91.6% identical to Applicants polypeptide of SEQ ID NO: 3. However, no prior art reference or sequence of record, taken alone or in combination teach the claimed invention or provide motivation to one of ordinary skill in the art to use the skills available in the area of enzymology or molecular biology, to make the invention obvious.

6. Drawings filed 7.17.2003 is acknowledged and are accepted for examination purpose(s) by the Examiner.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

7. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Tekchand Saidha (Ph.D.) whose telephone number is (571) 272-0940. The examiner can normally be reached on Monday-Friday from 8:15 am to 4:45 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ponnathapu Achutamurthy, can be reached at (571) 272-0928. The fax phone number for this Group in the Technology Center is 703 872-9306.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is 571 272-1600.



Tekchand Saidha

Primary Examiner, Art Unit 1652

Recombinant Enzymes, E03A61 Remsen Bld.

400 Dulany Street, Alexandria, VA 22314

Telephone : (571) 272-0940

January 5, 2006